Zamboni WC - Search Results

1

Pharmacologic and phenotypic study of docetaxel in patients with ovarian or primary peritoneal cancer.

Zamboni WC, Combest AJ, DeLoia JA, Edwards RP, Bridges AS, Zamboni BA, Walko CM, Yu AY, Krivak TC, Kelley JL. Zamboni WC, et al. Among authors: zamboni ba. Cancer Chemother Pharmacol. 2011 Nov;68(5):1255-62. doi: 10.1007/s00280-011-1609-9. Epub 2011 Mar 25. Cancer Chemother Pharmacol. 2011. PMID: 21437702

2

Phase I study of docetaxel and topotecan in patients with solid tumors.

Tkaczuk KH, Zamboni WC, Tait NS, Meisenberg BR, Doyle LA, Edelman MJ, Hausner PF, Egorin MJ, Van Echo DA. Tkaczuk KH, et al. Among authors: zamboni wc. Cancer Chemother Pharmacol. 2000;46(6):442-8. doi: 10.1007/s002800000180. Cancer Chemother Pharmacol. 2000. PMID: 11138457 Clinical Trial.

3

Effect of hemodialysis on topotecan disposition in a patient with severe renal dysfunction.

Herrington JD, Figueroa JA, Kirstein MN, Zamboni WC, Stewart CF. Herrington JD, et al. Among authors: zamboni wc. Cancer Chemother Pharmacol. 2001;47(1):89-93. doi: 10.1007/s002800000224. Cancer Chemother Pharmacol. 2001. PMID: 11221968

4

Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumors.

Jung LL, Ramanathan RK, Egorin MJ, Jin R, Belani CP, Potter DM, Strychor S, Trump DL, Walko C, Fakih M, Zamboni WC. Jung LL, et al. Among authors: zamboni wc. Cancer Chemother Pharmacol. 2004 Dec;54(6):487-96. doi: 10.1007/s00280-004-0835-9. Epub 2004 Aug 18. Cancer Chemother Pharmacol. 2004. PMID: 15322760 Clinical Trial.

5

Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial.

Ramanathan RK, Hwang JJ, Zamboni WC, Sinicrope FA, Safran H, Wong MK, Earle M, Brufsky A, Evans T, Troetschel M, Walko C, Day R, Chen HX, Finkelstein S. Ramanathan RK, et al. Among authors: zamboni wc. Cancer Invest. 2004;22(6):858-65. doi: 10.1081/cnv-200039645. Cancer Invest. 2004. PMID: 15641483

6

Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies.

Ramanathan RK, Ramalingam S, Egorin MJ, Belani CP, Potter DM, Fakih M, Jung LL, Strychor S, Jacobs SA, Friedland DM, Shin DM, Chatta GS, Tutchko S, Zamboni WC. Ramanathan RK, et al. Among authors: zamboni wc. Cancer Chemother Pharmacol. 2005 Apr;55(4):354-360. doi: 10.1007/s00280-004-0909-8. Epub 2004 Oct 27. Cancer Chemother Pharmacol. 2005. PMID: 15723261 Clinical Trial.

7

Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies.

Posey JA, Wang H, Hamilton J, Delgrosso A, Zhang R, Freda T, Zamboni WC. Posey JA, et al. Among authors: zamboni wc. Cancer Chemother Pharmacol. 2005 Aug;56(2):182-8. doi: 10.1007/s00280-004-0925-8. Epub 2005 Apr 19. Cancer Chemother Pharmacol. 2005. PMID: 15838660 Clinical Trial.

8

Phase I and pharmacokinetic study of weekly docetaxel, cisplatin, and daily capecitabine in patients with advanced solid tumors.

Fakih MG, Creaven PJ, Ramnath N, Trump D, Javle M, Strychor S, Repinski TV, Zamboni BA, Schwarz JK, French RA, Zamboni WC. Fakih MG, et al. Among authors: zamboni wc, zamboni ba. Clin Cancer Res. 2005 Aug 15;11(16):5942-9. doi: 10.1158/1078-0432.CCR-05-0116. Clin Cancer Res. 2005. PMID: 16115937 Clinical Trial.

9

Clinical and pharmacokinetic study evaluating the effect of food on the disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in patients with solid tumors.

Zamboni WC, Goel S, Iqbal T, Parise RA, Strychor S, Repinski TV, Egorin MJ, Mani S. Zamboni WC, et al. Cancer Chemother Pharmacol. 2006 May;57(5):631-9. doi: 10.1007/s00280-005-0084-6. Epub 2005 Oct 5. Cancer Chemother Pharmacol. 2006. PMID: 16205924 Clinical Trial.

10

Tumor, tissue, and plasma pharmacokinetic studies and antitumor response studies of docetaxel in combination with 9-nitrocamptothecin in mice bearing SKOV-3 human ovarian xenografts.

Zamboni WC, Strychor S, Joseph E, Parise RA, Egorin MJ, Eiseman JL. Zamboni WC, et al. Cancer Chemother Pharmacol. 2008 Aug;62(3):417-26. doi: 10.1007/s00280-007-0620-7. Epub 2007 Oct 24. Cancer Chemother Pharmacol. 2008. PMID: 17957368

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

165 results

Search Page

Filters